Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Explore this paper's citation graph
Summary
CPT-11 350 mg/m2 once every 3 weeks has an encouraging degree of activity in progressive metastatic CRC truly resistant to 5-FU with a relatively high rate of tumour growth control translated into clinical benefit.
- Type
- article
- Published
- 1999-01-01
- Cited by
- 111
- References
- 28
- Access
- Open access
- OpenAlex
- https://openalex.org/W2056131235
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:5314113
Keywords
Medicine, Irinotecan, Neutropenia, Internal medicine, Colorectal cancer
References
- Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer.
- Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
- Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
- Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
- Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.
- One-sample multiple testing procedure for phase II clinical trials.
- Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer
- The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer.
- CPT-11 (irinotecan) in the treatment of colorectal cancer.
- Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy.
- Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
- Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
- Overview of clinical trials using 5‐fluorouracil and leucovorin for the treatment of colorectal cancer
- Continuous infusion fluorouracil/leucovorin and bolus mitomycin‐C as a salvage regimen for patients with advanced colorectal cancer
- Topoisomerase I inhibitors: topotecan and irenotecan.
- Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
- Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.
- The chemotherapy of colon cancer can no longer be ignored.
- A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuridine alone.
Cited by
- New drugs and combinations in the palliative treatment of colon and rectal cancer.
- Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.
- Optimal treatment for poor prognosis isolated colorectal carcinoma liver metastases. Rationality for prospective neoadjuvant clinical trials
- Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours
- Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy
- Modeling biological rhythms in failure time data
- Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial
- Current status of second-line therapy for metastatic colorectal cancer.
- Management of Colorectal Cancer
- Prolonging the exposure to anti-cancer agents
- Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines.
- Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer
- Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
- Irinotecan in the treatment of colorectal cancer: clinical overview.
- Phase II Study of Irinotecan and Mitomycin C in 5-Fluorouracil-Pretreated Patients with Advanced Colorectal and Gastric Cancer
- Systemic treatment of advanced colorectal cancer: Incorporating new agents into the therapeutic strategy
- Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy.
- Second-line therapy for advanced colorectal carcinoma
- Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
- Clinical benefits of stabilisation with second line chemotherapy in patients with metastatic colorectal cancer.
Related papers
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
- Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
- Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase III trial
- Combination chemotherapy of irinotecan combined with bolus 5-fluorouracil, continuous infusion 5-fluorouracil, and high dose leucovorin every two weeks in recurrent or metastatic colorectal cancer.
- Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
- Treatment of a Gilbert's Syndrome Patient with Irinotecan, Leucovorin and 5-Fluorouracil
- IRINOTECAN, FLUOROURACIL AND LEUCOVO- RIN IN PATIENTS WITH METASTATIC COLOREC- TAL CANCER
- A phase II study of biweekly irinotecan (CPT-11) and 5-fluorouracil (5-FU) as first line treatment in advanced or metastatic colorectal cancer (CRC)